Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Matthew Malta

Internal Medicine Annapolis, MD Medical Doctor

NPI 1780673095 CMS profile 699195

132 Holiday Ct, Suite 201, Annapolis, MD 21401

Open in the dashboard

General payments

$577

10 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Malta of Annapolis, MD is reported in the CMS Open Payments database as having received $577 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $290 4
2023 General $150 3
2022 General $137 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Malta
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Matthew Malta were reported at $290. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Matthew Malta Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $137 $141 $42–$496 $149
2023 $150 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $290 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $238 3 payments
  2. Medtronic, Inc. $127 2 payments
  3. AstraZeneca Pharmaceuticals LP $123 1 payment
  4. Boston Scientific Corporation $40 1 payment
  5. AbbVie, Inc. $30 2 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $577 10 payments
Products named General payments · program years 2022–2025
  1. AREXVY $132 2 payments
  2. ENDURANT IIS $127 2 payments
  3. AIRSUPRA $123 1 payment
  4. SHINGRIX $107 1 payment
  5. ENROUTE Transcarotid Neuroprotection System $40 1 payment
  6. QULIPTA $30 2 payments
  7. XIFAXAN $19 1 payment
  8. TRULANCE $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

3,212

Median for Internal Medicine: 777

Drug cost

$393,628

Median for Internal Medicine: $73,373

Branded share of claims

21.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 90 $88,581
Ozempic Semaglutide Brand 69 $86,972
Mounjaro Tirzepatide Brand 61 $66,427
Xarelto Rivaroxaban Brand 42 $54,087
Gemtesa Vibegron Brand 31 $24,851
Myrbetriq Mirabegron Brand 22 $12,662
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 19 $3,939
Atorvastatin Calcium Generic 217 $2,875
Rosuvastatin Calcium Generic 98 $2,660
Valsartan Generic 75 $2,518

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$111,508

Of which drugs: $28,495

Medicare patients

254

Average age 79

Services billed

1,662

120 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 24%
Diabetes 23%
Atrial fibrillation 21%
Cancer 18%
Depression 13%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 115 117 $17,625
Vaccine for influenza for injection into muscle 90662 Office 103 103 $8,427
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 39 39 $854
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 14 14 $332

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record